MedTrace Logo

Early-stage Ovarian Clear Cell Carcinoma (OCCC) Patients at Risk of Recurrence

NCT06237946 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 272

Last updated 2024-02-23

No results posted yet for this study

Summary

The goal of this observational study is to determine the risk of recurrence in early-stage OCCC (Ovarian Clear Cell Carcinoma) patients who received postoperative adjuvant treatment.

Participants were received platinum-based adjuvant therapy following debulking surgery will be included for the study.

Conditions

  • FIGO Stage IC2 to II Ovarian Clear Cell Carcinoma

Sponsors & Collaborators

  • Chang Gung Memorial Hospital

    collaborator OTHER

  • Tokyo University

    collaborator OTHER

  • Samsung Medical Center

    collaborator OTHER

  • National Taiwan University Hospital

    lead OTHER

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-15
Primary Completion
2024-10-31
Completion
2024-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06237946 on ClinicalTrials.gov